Analysis Tools
hematopoietic system
|
• in pIpC-treated mice to a lesser extent than in mice with wild-type Csf3r
|
|
• in pIpC-treated mice to a lesser extent than in mice with wild-type Csf3r
|
|
• in pIpC-treated mice to a lesser extent than in mice with wild-type Csf3r
|
|
• pIpC-treated mice exhibit an increase in Gr1+CD11b+ myeloid cells in the spleen compared with Csf3rtm1Link homozygotes
|
cellular
|
• in pIpC-treated mice to a lesser extent than in mice with wild-type Csf3r
|
immune system
|
• in pIpC-treated mice to a lesser extent than in mice with wild-type Csf3r
|
|
• in pIpC-treated mice to a lesser extent than in mice with wild-type Csf3r
|
|
• in pIpC-treated mice to a lesser extent than in mice with wild-type Csf3r
|
|
• pIpC-treated mice exhibit an increase in Gr1+CD11b+ myeloid cells in the spleen compared with Csf3rtm1Link homozygotes
|
growth/size/body
|
• in pIpC-treated mice to a lesser extent than in mice with wild-type Csf3r
|
|
• in pIpC-treated mice to a lesser extent than in mice with wild-type Csf3r
|
